A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

Completed · Phase 1 · Has a placebo group

Conditions studied: Fragile X Syndrome

In brief

The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral suspension

Key facts

Study ID

NCT00965432

Run by

Seaside Therapeutics, Inc.

People needed

40

Starts

2009-09-01

Expected to finish

2010-02-01

Last updated by the study team

2010-02-08

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Normal, healthy males 18-50 years old, inclusive.
• Able to comprehend and willing to sign an Informed Consent Form (ICF).

You may not qualify if…

• Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator).

Where it is running

• Covance Clinical Research Unit — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.